Imunon Company Leadership
| IMNN Stock | USD 0.83 0.02 2.47% |
Imunon employs about 33 people. The company is managed by 13 executives with a total tenure of roughly 77 years, averaging almost 5.0 years of service per executive, having 2.54 employees per reported executive. Analysis of Imunon's management performance can provide insight into the firm performance.
Imunon |
Imunon Management Team Effectiveness
The company has return on total asset (ROA) of (0.6708) % which means that it has lost $0.6708 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4812) %, meaning that it created substantial loss on money invested by shareholders. Imunon's management efficiency ratios could be used to measure how well Imunon manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to drop to -0.93. In addition to that, Return On Capital Employed is likely to grow to -1.38. At this time, Imunon's Total Assets are very stable compared to the past year. As of the 27th of November 2024, Other Current Assets is likely to grow to about 2.7 M, while Non Current Assets Total are likely to drop about 3.5 M.As of the 27th of November 2024, Common Stock Shares Outstanding is likely to grow to about 9.5 M, while Net Loss is likely to drop (33.9 M).
Imunon Workforce Comparison
Imunon Inc is rated fourth overall in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 393. Imunon holds roughly 33.0 in number of employees claiming about 8% of equities under Health Care industry.
Imunon Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Imunon insiders, such as employees or executives, is commonly permitted as long as it does not rely on Imunon's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Imunon insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pellizzari Christine A over two months ago Disposition of tradable shares by Pellizzari Christine A of Imunon subject to Rule 16b-3 | ||
Anwer Khursheed over two months ago Acquisition by Anwer Khursheed of 40653 shares of Imunon at 1.04 subject to Rule 16b-3 | ||
Lindborg Stacy over three months ago Disposition of tradable shares by Lindborg Stacy of Imunon subject to Rule 16b-3 | ||
Braun Donald P over three months ago Acquisition by Braun Donald P of 3500 shares of Imunon at 1.22 subject to Rule 16b-3 | ||
Braun Donald P over three months ago Acquisition by Braun Donald P of 6250 shares of Imunon subject to Rule 16b-3 | ||
Gaiero David G over three months ago Disposition of tradable shares by Gaiero David G of Imunon subject to Rule 16b-3 | ||
Le Goff Corinne over six months ago Acquisition by Le Goff Corinne of 90000 shares of Imunon at 1.32 subject to Rule 16b-3 | ||
Michael Tardugno over six months ago Acquisition by Michael Tardugno of 12500 shares of Imunon at 0.86 subject to Rule 16b-3 |
Imunon Notable Stakeholders
An Imunon stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Imunon often face trade-offs trying to please all of them. Imunon's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Imunon's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Stacy Lindborg | CEO President | Profile | |
| PharmD MBA | President CEO | Profile | |
| Michael Tardugno | Executive Chairman | Profile | |
| David CPA | CFO Secretary | Profile | |
| Jeffrey CPA | Executive CFO | Profile | |
| CPA CPA | Exec CFO | Profile | |
| Nicholas MD | Ex Officer | Profile | |
| Susan Eylward | General Secretary | Profile | |
| David Gaiero | Chief Officer | Profile | |
| Sebastien MD | Executive Officer | Profile | |
| Timothy CPA | Chief Controller | Profile | |
| Marianne Lambertson | Vice Relations | Profile | |
| Khursheed MBA | Executive Officer | Profile |
About Imunon Management Performance
The success or failure of an entity such as Imunon Inc often depends on how effective the management is. Imunon management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Imunon management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Imunon management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.89) | (0.93) | |
| Return On Capital Employed | (1.45) | (1.38) | |
| Return On Assets | (0.89) | (0.93) | |
| Return On Equity | (1.46) | (1.53) |
Imunon Workforce Analysis
Traditionally, organizations such as Imunon use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Imunon within its industry.Imunon Manpower Efficiency
Return on Imunon Manpower
| Revenue Per Employee | 3.8K | |
| Revenue Per Executive | 9.6K | |
| Net Loss Per Employee | 591.4K | |
| Net Loss Per Executive | 1.5M | |
| Working Capital Per Employee | 328.8K | |
| Working Capital Per Executive | 834.6K |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.014 | Return On Assets (0.67) | Return On Equity (1.48) |
The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.